Guiding Precision Medicine in Non−Small Cell Lung Cancer: Recent Updates in New and Emerging Biomarkers
A 1.0-hour Accredited On-Demand Virtual Symposium conducted in conjunction with HOPA 2021
Novartis Pharmaceuticals Corporation and Amgen.
Faculty Presenters
Jason Bergsbaken, PharmD, BCOP
Pharmacy Coordinator, Regional Oncology Services
UW Health
Madison, Wisconsin
Josiah D. Land, PharmD, BCOP
Clinical Pharmacy Specialist
Thoracic Medical Oncology
Memorial Sloan Kettering Cancer Center
New York, New York
Program Description
The treatment of non−small cell lung cancer (NSCLC) involves the use of molecular testing, which allows for patient-specific therapy. Specifically, molecular testing identifies either predictive biomarkers or prognostic markers, which can be used to determine optimal treatments for each patient, and potentially overall outcomes. Pharmacists are heavily involved in the care of patients with NSCLC, and require an understanding of biomarker testing in order to assist with treatment decisions. This activity will focus on an overall review of molecular testing in NSCLC, specific targeted therapies, and the role of the pharmacist in caring for patients receiving these targeted therapies.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 30, 2021
Expiration date: April 30, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify trends in testing for actionable biomarkers and trends in testing in non−small cell lung cancer (NSCLC)
- Apply results of biomarker testing in the treatment selection of patients with NSCLC
- Investigate approved and emerging targeted therapies in the treatment of NSCLC
- Maximize the role of the oncology pharmacist in treatment decisions for patients with NSCLC
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-177-H01-P. The activity is available for CE credit through April 30, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Consultant: Creative Educational Concepts
Jason Bergsbaken, PharmD, BCOP, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Meg Croom Taylor, PharmD, CPP; Ann Marciano; Crissy Wilson; Kelly McCormick; Susan Pordon; and Brianna Winters have no financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
